Clinical Trial Update: Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating boosting of Atazanavir 300 mg with either 50 mg or 100 mg ritonavir daily in HIV-infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Norvir (ritonavir)
• REYATAZ (atazanavir)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: HIV Infection | Phase 1 | Status: COMPLETED